Practical Modifications to the Time-To-Event Continual Reassessment Method for Phase I Cancer Trials With Fast Patient Accrual and Late-Onset Toxicities

Statistics in Medicine - United States
doi 10.1002/sim.4255
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicities

Biometrics
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology ImmunologyBiological SciencesMedicineAgricultural
2000English

A Trivariate Continual Reassessment Method for Phase I/Ii Trials of Toxicity, Efficacy, and Surrogate Efficacy

Statistics in Medicine
EpidemiologyStatisticsProbability
2012English

Escalation With Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials

PLoS ONE
Multidisciplinary
2014English

A New Pragmatic Design for Dose Escalation in Phase 1 Clinical Trials Using an Adaptive Continual Reassessment Method

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Miscellanea. A Stopping Rule for the Continual Reassessment Method

Biometrika
StatisticsProbabilityUncertaintyApplied MathematicsBiological SciencesAgriculturalMathematics
1998English

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials With Time‐to‐Event Outcomes

Oncologist
Cancer ResearchMedicineOncology
2019English

Robust EM Continual Reassessment Method in Oncology Dose Finding

Journal of the American Statistical Association
UncertaintyStatisticsProbability
2011English

Continual Reassessment Method for Dose Escalation Clinical Trials in Oncology: A Comparison of Prior Skeleton Approaches Using AZD3514 Data

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Phase I Cancer Clinical Trials

British Journal of Cancer
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy